Text Size
13 studies found for:    weill | Open Studies | "Hepatitis"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Unknown † Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)
Condition: Hepatitis C
Intervention: Drug: Telaprevir
2 Unknown † The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
Conditions: Hepatic Encephalopathy;   Hepatitis C;   Liver Cirrhosis
Intervention: Drug: Rifaximin (drug)
3 Recruiting Armodafinil for Patients Starting Hepatitis C Virus Treatment
Condition: Hepatitis C
Interventions: Drug: Armodafinil;   Drug: Placebo
4 Recruiting HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network
Condition: Hepatitis C
Intervention:
5 Recruiting A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B
Conditions: Hepatitis B;   HBV
Interventions: Drug: Single Ascending Dose (SAD) Cohorts GS-9620;   Drug: Multiple Ascending Dose (MAD) Cohorts
6 Recruiting A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection
Condition: Hepatitis B
Interventions: Drug: Single Ascending Dose (SAD) Cohorts GS-9620;   Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620
7 Recruiting Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Condition: Hepatitis B Virus
Interventions: Drug: pegIFN;   Drug: pegIFNα-2a;   Drug: PegIFN lambda;   Drug: Entecavir
8 Recruiting Safety and Efficacy Study of BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Untreated Hepatitis C Patients Coinfected With HIV Virus
Condition: Hepatitis C, Genotype 1
Interventions: Drug: BMS-790052 (Daclatasvir);   Drug: Ribavirin;   Drug: Peg-Interferon alfa 2a
9 Recruiting Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives)
Condition: Hepatitis C Virus
Interventions: Drug: Asunaprevir (ASV);   Drug: Daclatasvir (DCV);   Drug: PBO matching ASV;   Drug: Placebo (PBO) matching DCV;   Drug: Pegylated-interferon alfa 2a (PegIFN);   Drug: Ribavirin (RBV)
10 Recruiting Phase 2 Study of SOF+GS-5816 in Treatment Naive Subjects With Chronic HCV
Condition: Hepatitis C
Intervention: Drug: SOF in combination with GS-5816
11 Recruiting Open-Label Study of GS-7977+ Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Condition: Chronic Hepatitis C
Interventions: Drug: GS-7977 in combination with ribavirin;   Drug: GS-7977 400mg QD+ RBV BID+ PEG
12 Unknown † Anti-D for Treating Thrombocytopenia in Adults Infected With Hepatitis C Virus With or Without HIV Co-Infection
Conditions: Thrombocytopenia;   Hepatitis C;   HIV Infections
Intervention: Drug: Anti-D
13 Recruiting Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium
Condition: Hepatic Fibrosis
Intervention: Procedure: MRI of liver
To Top

† Indicates status has not been verified in more than two years